Lubabegron

Lubabegron (trade name Experior) is a veterinary drug used to reduce ammonia emissions from animals and their waste.[1] Ammonia emissions are a concern in agricultural production because of detrimental effects on the environment, human health, and animal health.[2]

Lubabegron
Clinical data
Trade namesExperior
Other namesLY-488756
ATC code
  • None
Legal status
Legal status
  • Veterinary use only
Identifiers
  • 2-[4-[2-[[(2S)-2-Hydroxy-3-(2-thiophen-2-ylphenoxy)propyl]amino]-2-methylpropyl]phenoxy]pyridine-3-carbonitrile
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H29N3O3S
Molar mass499.63 g·mol−1

Lubabegron was approved by the U.S. Food and Drug Administration in 2018 for use in feedlot cattle.[3][4] It is the first drug approved for reducing ammonia emissions.[5] It is also approved for use in Canada.[6]

Lubabegron is a beta-adrenergic receptor agonist/antagonist.[7] The antagonist activity of lubabegron at β1 and β2 receptors prevents the stimulation of the β-AR found in the heart (β1) and trachea/bronchi (β2) of humans and, in doing so, avoids the potential negative side effects associated with β1 and β2 receptor activation. The β1-AR and β2-AR antagonist behavior of lubabegron could decrease lipolysis in adipose tissue, whereas the β3-AR agonist activity could increase skeletal muscle hypertrophy, possibly due to the differences in the second messenger systems and enzyme expression in skeletal muscle compared with adipose tissues.[8]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.